FACS Aria II for Flow Cytometry Core Facility

描述(由申请人提供)：南伊利诺伊大学医学院请求支持为我们的核心实验室购买新的流式细胞仪。申请的BD FACSAria II将取代1993年用共享仪器赠款购买的FACSVantage，至今仍作为我们唯一的细胞分选器使用，记录了NCRR令人难以置信的投资回报。然而，这个单元已经相当过时，不再满足我们教职员工的研究需求。此外，2009年后，Vantage将不再受到供应商的支持。FACSAria II将支持由7名由NIH资助的具有不同研究兴趣的教职员工组成的核心，他们的不同资金来源(NCI、NHLBI和NIAID)表明了这一点。FACSAria II技术将有效地提高他们的数据收集质量、他们可用的研究选择以及他们的整体生产率。获得高质量的分选细胞群体的能力将有助于我们在了解癌症、传染病、细胞发育以及细胞和生物分子过程的其他方面的原因和过程方面取得更快的进展。由于FACSAria II允许快速、可靠的细胞分选，它减少了旧系统固有的细胞损失和变异性。通过提高分选的时间和空间分辨率，该技术允许从不同的人群中收集特定但稀有的细胞类型，从而支持对治疗效果和正常与病理过程的精确和准确的表征。这些好处将使我们的NIH资助的研究人员和其他研究人员能够以其他方式推进他们各自的研究领域，而不是使用SIUSM目前可用的工具。

DESCRIPTION (provided by applicant): The Southern Illinois University School of Medicine requests support to purchase a new flow cytometer for our core lab. The requested BD FACSAria II will replace a FACSVantage that was purchased with a Shared Instrumentation Grant in 1993 and remains in use today as our only cell sorter, documenting an incredible return-on-investment for NCRR. However, this unit is quite outdated and no longer meets the research needs of our faculty. Furthermore, after 2009 the Vantage will no longer be supported by the vendor. The FACSAria II will support a core of 7 NIH-funded faculty members with diverse research interests, as indicated by their varied sources of NIH funding (NCI, NHLBI, and NIAID). FACSAria II technology will effectively increase the quality of their data collection, their available research options, and their overall productivity. The ability to obtain high-quality populations of sorted cells will contribute to more rapid advances in our understanding of the causes and course of cancer, infectious diseases, cell development, and other aspects of cellular and biomolecular processes. Because the FACSAria II allows rapid, reliable cell sorting, it reduces the cell loss and variability inherent in older systems. By increasing the temporal and spatial resolution of the sorting, the technology allows collection of specific but rare cell types from a heterogeneous population, thereby supporting precise and accurate characterization of therapeutic effects and normal versus pathological processes. These benefits will allow our NIH- funded and other investigators to advance their respective research areas in ways not otherwise possible with the tools currently available to them at SIUSM.